FindTrial
Sign In

The Value of CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Early Neurosyphilis

The Value of CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Early Neurosyphilis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037402
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurosyphilis

Interventions

Gold Standard:Neurosyphilis was defined as having a reactive or nonreactive CSF-VDRL
Index test:CSF&#32
CXCL13,&#32
CXCL10&#32
and&#32
CXCL8&#32
CSF/serum&#32
ratio&#32
of&#32
&#32

Sponsors

Shanghai Skin Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with early or latent syphilis; 2. Aged 18-65 years old; 3. Sign informed consent; 4. Consent to lumbar puncture; 5. No severe organ dysfunction or failure.

Exclusion criteria

Exclusion criteria: 1. Duration of pregnancy and lactation; 2. Severe organ dysfunction or failure; 3. Contraindications for liver biopsy.

Design outcomes

Primary

MeasureTime frame
cerebrospinal fluid CXCL13;cerebrospinal fluid CXCL10;cerebrospinal fluid CXCL8;—

Secondary

MeasureTime frame
serum CXCL13;serum CXCL10;—

Contacts

Public ContactMEI SHI

Shanghai Skin Disease Hospital

shimeipfb@sina.cn+86 18017336578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026